Adaptimmune Announces Sale of Cell Therapies to US WorldMeds
Deal News | Jul 28, 2025 | Ropes & Gray
Adaptimmune Therapeutics plc has entered into a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies, including all related intellectual property rights, to US WorldMeds for $55 million in cash. Ropes & Gray served as legal advisor on the transaction. The agreement also includes potential future milestone payments up to $30 million contingent upon specific achievements. The deal, announced on July 28, is expected to conclude by the end of the week.
Sectors
- Biotechnology
- Legal Services
Geography
- United Kingdom – Home country of Adaptimmune Therapeutics plc, the seller in the transaction.
- United States – Country associated with US WorldMeds, the buyer in the transaction.
Industry
- Biotechnology – The article focuses on Adaptimmune Therapeutics, a company engaged in the development of cell therapies, a core aspect of the Biotechnology industry.
- Legal Services – Ropes & Gray provided legal advisory services in the transaction, categorizing the involvement in the Legal Services industry.
Financials
- $55 million – Cash payment to be made by US WorldMeds at the closing of the deal.
- Up to $30 million – Potential future payments contingent upon achievement of specific milestones.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Adaptimmune Therapeutics plc | Target | Company | A biotechnology company known for its expertise in cell therapies. |
| US WorldMeds | Bidding Company/Buyer | Company | A pharmaceutical company acquiring cell therapy assets from Adaptimmune Therapeutics. |
| Ropes & Gray | Legal Advisor | Company | Provided legal advisory services for the transaction between Adaptimmune and US WorldMeds. |